NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Lakeland Industries, Inc. (“Lakeland” or the “Company”) (NASDAQ: LAKE) securities between December 1, 2023, and December 9, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants failed to disclose to investors ...

NEW YORK, Feb. 16, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Maryland on behalf of all persons or entities who purchased or otherwise acquired REGENXBIO Inc. (“REGENXBIO” or the “Company”) (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026, inclusive (the “Class Period”). The Complaint alleges that Defendants provided overwhelmingly positive statements to inve ...

Core Viewpoint - A securities class action lawsuit has been filed against Inovio Pharmaceuticals, alleging that the company misled investors regarding the manufacturing deficiencies of its CELLECTRA device and the regulatory prospects of its INO-3107 BLA [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Eastern District of Pennsylvania on behalf of all individuals or entities who purchased Inovio securities between October 10, 2023, and December 26, 2025 [1]. - The complaint claims that Inovio failed to disclose significant issues, including deficiencies in manufacturing for the CELLECTRA device and the unlikelihood of submitting the INO-3107 BLA to the FDA by the second half of 2024 [2]. Group 2: Allegations Against Inovio - Allegations include that Inovio lacked sufficient information to justify the eligibility of the INO-3107 BLA for FDA accelerated approval or priority review, leading to overstated regulatory and commercial prospects [2]. - The public statements made by Inovio were claimed to be materially false and misleading throughout the relevant period [2]. Group 3: Investor Information - Investors who acquired shares of Inovio are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on April 7, 2026 [3].

NEW YORK, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Nevada on behalf of all persons or entities who purchased or otherwise acquired Richtech Robotics Inc. (“Richtech” or the “Company”) (NASDAQ: RR) securities between January 27, 2026 and 12:00 PM EST on January 29, 2026, inclusive (the “Class Period”). The Complaint alleges that Defendants misled investors: (i) the Compan ...

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of New York on behalf of all persons or entities who purchased or otherwise acquired Agilon Health, Inc. (“Agilon” or the “Company”) (NYSE: AGL) securities between February 26, 2025, and August 4, 2025. The Complaint alleges that (i) Defendants recklessly issued guidance for 2025 that they knew or should have known ...

Core Viewpoint - A securities class action lawsuit has been filed against Stride, Inc. for allegedly misleading investors regarding its operational performance and compliance during the Class Period from October 22, 2024, to October 28, 2025 [1][2]. Group 1: Allegations Against Stride, Inc. - The lawsuit claims that Stride misrepresented itself as "one of the nation's most successful technology-based education companies" and highlighted its "deep educational, regulatory, and policy expertise" to mislead the market [2]. - Specific allegations include: 1. Inflating enrollment numbers 2. Cutting staff costs beyond required statutory limits 3. Ignoring compliance requirements 4. Losing existing and potential student enrollments [2]. Group 2: Legal Proceedings - Investors who acquired Stride shares during the Class Period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 12, 2026 [3]. - The lead plaintiff will represent the interests of other class members in the litigation [3].

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Integer Holdings Corporation (“Integer” or the “Company”) (NYSE: ITGR) securities between July 25, 2024 and October 22, 2025, inclusive (the “Class Period”). The Complaint alleges that Defendants failed to disclose that: (i) the Co ...

Core Viewpoint - A securities class action lawsuit has been filed against Skye Bioscience, Inc. for allegedly making materially false and misleading statements regarding its business and the effectiveness of its product, nimacimab [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Southern District of California on behalf of all individuals or entities that purchased Skye securities between November 4, 2024, and October 3, 2025 [1]. - The complaint alleges that the defendants overstated the effectiveness and prospects of nimacimab, leading to materially false and misleading public statements [2]. Group 2: Investor Information - Investors who acquired shares of Skye are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on January 16, 2026 [3].

Group 1 - A securities class action lawsuit has been filed against Semler Scientific, Inc. for the period between March 10, 2021, and April 15, 2025 [1] - The complaint alleges that Semler Scientific failed to disclose a material investigation by the U.S. Department of Justice regarding violations of the False Claims Act [2] - Defendants' public statements are claimed to be materially false and misleading due to the lack of disclosure about the investigation [2] Group 2 - Investors who acquired shares of Semler Scientific are encouraged to contact the law firm before the lead plaintiff motion deadline of October 28, 2025 [3] - The lead plaintiff will act on behalf of other class members in directing the litigation [3]

Core Viewpoint - A securities class action lawsuit has been filed against C3.ai, Inc. for allegedly misleading investors regarding its revenue outlook and the impact of CEO Thomas M. Siebel's health on the company's profitability [1][2]. Group 1: Lawsuit Details - The lawsuit was filed in the United States District Court for the Northern District of California on behalf of individuals or entities that acquired C3.ai shares between February 26, 2025, and August 8, 2025 [1]. - The Complaint claims that the defendants created a false impression of C3.ai's financial health and growth potential while downplaying risks associated with the CEO's health [2]. Group 2: Investor Information - Investors who purchased C3.ai shares are encouraged to contact the law firm before the lead plaintiff motion deadline on October 21, 2025 [3]. - The lead plaintiff will represent the interests of other class members in the litigation process [3].